Imbruvica

Ibrutinib, the active ingredient in Imbruvica, is a Bruton’s tyrosine kinase (BTK) inhibitor presented as a capsule for oral use. It is employed in the treatment of several B‑cell malignancies and related immune disorders. GNH USA supplies Imbruvica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Imbruvica (ibrutinib) targets B‑cell receptor signaling and is indicated for several B‑cell malignancies.

- Chronic lymphocytic leukemia (CLL): improves disease control and prolongs progression‑free survival in adult patients. - Mantle cell lymphoma (MCL): induces tumor regression in relapsed or refractory disease. - Waldenström macroglobulinemia: reduces IgM levels and disease activity. - Marginal zone lymphoma: provides disease control in adult patients. - Chronic graft‑versus‑host disease (cGVHD): alleviates symptoms in steroid‑refractory adult patients.

Common side effects are generally mild to moderate and may affect treatment tolerability.

Common Side Effects: - Diarrhea: loose stools occurring during therapy. - Bleeding: increased tendency to bruise or bleed. - Atrial fibrillation: irregular heart rhythm episodes. - Nausea: feeling of sickness or urge to vomit. - Rash: skin irritation or redness. - Fatigue: persistent tiredness.

Serious or Rare Side Effects: - Severe infections: opportunistic or life‑threatening bacterial, fungal, or viral infections. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances. - Hepatotoxicity: elevated liver enzymes or liver injury. - Secondary malignancies: emergence of new cancers. - Major hemorrhage: gastrointestinal or intracranial bleeding. - Cardiac arrhythmias: serious rhythm disturbances beyond atrial fibrillation.

Before initiating Imbruvica, clinicians should assess several safety parameters.

- Monitor blood counts: perform regular complete blood count tests. - Assess bleeding risk: evaluate concurrent anticoagulant or antiplatelet use. - Screen cardiac history: watch for atrial fibrillation or other arrhythmias. - Evaluate liver function: conduct periodic liver enzyme assessments. - Counsel on infection signs: advise prompt reporting of fever or unexplained illness. - Store at ambient temperature: keep below 25°C, protect from moisture and keep in original packaging.

Imbruvica may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Anticoagulants (warfarin, DOACs): heightened bleeding risk. - Strong CYP3A4 inhibitors (ketoconazole, clarithromycin): increased ibrutinib exposure. - Strong CYP3A4 inducers (rifampin, phenytoin): reduced drug efficacy. - Antifungal azoles (itraconazole, posaconazole): may raise plasma levels.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (fluconazole, erythromycin): may modestly increase exposure. - Moderate CYP3A4 inducers (carbamazepine, phenobarbital): may modestly decrease exposure. - CYP2C8 substrates (paclitaxel): potential altered metabolism. - Live vaccines: possible reduced vaccine efficacy.